German court blocks Sanofi’s cholesterol drug after Amgen lawsuitAmgen has lived up to its litigious reputation after it successfully persuaded a German court to uphold a Share XGerman court blocks Sanofi’s cholesterol drug after Amgen lawsuithttps://pharmaphorum.com/news/german-court-blocks-sanofis-cholesterol-drug-after-amgen-lawsuit/
GSK hires former Genentech expert for AI unitGlaxoSmithKline has hired computational drug design specialist Dr Kim Branson to expand its artificial intelligence and machine learning Share XGSK hires former Genentech expert for AI unithttps://pharmaphorum.com/news/gsk-hires-former-genentech-expert-for-ai-unit/
FDA reviews Sanofi’s multiple myeloma drug isatuximabThe FDA has begun its review of Sanofi’s multiple myeloma drug isatuximab, as the French pharma prepares for Share XFDA reviews Sanofi’s multiple myeloma drug isatuximabhttps://pharmaphorum.com/news/fda-reviews-sanofis-multiple-myeloma-drug-isatuximab/
Immediately after EU nod, England’s NHS funds Sanofi skin cancer drugPatients in England will be among those who are first to benefit from Sanofi and Regeneron’s new cancer Share XImmediately after EU nod, England’s NHS funds Sanofi skin cancer drughttps://pharmaphorum.com/news/immediately-after-eu-nod-englands-nhs-funds-sanofi-skin-cancer-drug/
Almirall takes option on Dermira’s eczema drug lebrikizumabSpain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe, Share XAlmirall takes option on Dermira’s eczema drug lebrikizumabhttps://pharmaphorum.com/news/almirall-takes-option-on-dermiras-eczema-drug-lebrikizumab/
Sanofi/Regeneron asthma trial casts doubt on IL-33 class prospectsThe good news for Sanofi and Regeneron is that their interleukin-33-targeting drug seems to work in asthma. The Share XSanofi/Regeneron asthma trial casts doubt on IL-33 class prospectshttps://pharmaphorum.com/news/sanofi-regeneron-asthma-trial-casts-doubt-il-33-class-prospects/
Sanofi hands back neurology gene therapy rights to VoyagerSanofi’s Genzyme unit has handed back rights to two neurology gene therapies to US biotech Voyager Therapeutics, as Share XSanofi hands back neurology gene therapy rights to Voyagerhttps://pharmaphorum.com/news/sanofi-hands-back-neurology-gene-therapy-rights-to-voyager/
Sanofi and Google join forces to create ‘Innovation Lab’Sanofi and Google are to create a virtual innovation lab, aiming to transform how future medicines and health Share XSanofi and Google join forces to create ‘Innovation Lab’https://pharmaphorum.com/news/sanofi-and-google-join-forces-to-create-innovation-lab/
Sanofi, Lilly and Novo make cases for diabetes drugs at ADAThe American Diabetes Association (ADA) annual conference has dominated the medical research headlines this weekend as pharma and Share XSanofi, Lilly and Novo make cases for diabetes drugs at ADAhttps://pharmaphorum.com/news/sanofi-lilly-and-novo-diabetes/
